• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

改良的肿瘤负荷、肝功能、全身炎症和肿瘤生物学评分联合预测肝癌切除术后的长期预后。

Modified integrated tumor burden, liver function, systemic inflammation, and tumor biology score to predict long-term outcomes after resection for hepatocellular carcinoma.

机构信息

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA; Department of Surgery, University of Verona, Verona, Italy.

出版信息

HPB (Oxford). 2023 Dec;25(12):1484-1493. doi: 10.1016/j.hpb.2023.07.901. Epub 2023 Jul 22.

DOI:10.1016/j.hpb.2023.07.901
PMID:37544855
Abstract

BACKGROUND

A preoperative predictive score for hepatocellular carcinoma (HCC) can help stratify patients who undergo resection relative to long-term outcomes and tailor treatment strategies.

METHODS

Patients who underwent curative-intent hepatectomy for HCC between 2000 and 2020 were identified from an international multi-institutional database. A risk score (mFIBA) was developed using an Eastern cohort and then validated using a Western cohort.

RESULTS

Among 957 patients, 443 and 514 patients were included from the Eastern and Western cohorts, respectively. On multivariable analysis, alpha-feto protein (HR1.97, 95%CI 1.42-2.72), neutrophil-to-lymphocyte ratio (HR1.74, 95%CI 1.28-2.38), albumin-bilirubin grade (HR1.66, 95%CI 1.21-2.28), and imaging tumor burden score (HR1.25, 95%CI 1.12-1.40) were associated with OS. The c-index in the Eastern test and Western validation cohorts were 0.69 and 0.67, respectively. Notably, mFIBA score outperformed previous HCC staging systems. 5-year OS incrementally decreased with an increase in mFIBA. On multivariable Cox regression analysis, the mFIBA score was associated with worse OS (HR1.18, 95%CI 1.13-1.23) and higher risk of recurrence (HR1.16, 95%CI 1.11-1.20). An easy-to-use calculator of the mFIBA score was made available online (https://yutaka-endo.shinyapps.io/mFIBA_score/).

DISCUSSION

The online mFIBA calculator may help surgeons with clinical decision-making to individualize perioperative treatment strategies for patients undergoing resection of HCC.

摘要

背景

肝细胞癌 (HCC) 的术前预测评分可帮助对接受切除术的患者进行分层,以评估其与长期预后的关系,并制定治疗策略。

方法

从一个国际多机构数据库中确定了 2000 年至 2020 年间接受根治性肝切除术治疗 HCC 的患者。使用东方队列开发了一个风险评分 (mFIBA),然后使用西方队列对其进行验证。

结果

在 957 例患者中,分别有 443 例和 514 例患者来自东方队列和西方队列。多变量分析显示,甲胎蛋白 (HR1.97, 95%CI 1.42-2.72)、中性粒细胞与淋巴细胞比值 (HR1.74, 95%CI 1.28-2.38)、白蛋白-胆红素分级 (HR1.66, 95%CI 1.21-2.28) 和影像学肿瘤负荷评分 (HR1.25, 95%CI 1.12-1.40) 与 OS 相关。在东方测试和西方验证队列中的 C 指数分别为 0.69 和 0.67。值得注意的是,mFIBA 评分优于以前的 HCC 分期系统。mFIBA 评分越高,5 年 OS 逐渐降低。多变量 Cox 回归分析显示,mFIBA 评分与较差的 OS (HR1.18, 95%CI 1.13-1.23) 和更高的复发风险 (HR1.16, 95%CI 1.11-1.20) 相关。mFIBA 评分的在线计算器已在网上提供 (https://yutaka-endo.shinyapps.io/mFIBA_score/)。

讨论

在线 mFIBA 计算器可以帮助外科医生进行临床决策,为接受 HCC 切除术的患者制定个体化的围手术期治疗策略。

相似文献

1
Modified integrated tumor burden, liver function, systemic inflammation, and tumor biology score to predict long-term outcomes after resection for hepatocellular carcinoma.改良的肿瘤负荷、肝功能、全身炎症和肿瘤生物学评分联合预测肝癌切除术后的长期预后。
HPB (Oxford). 2023 Dec;25(12):1484-1493. doi: 10.1016/j.hpb.2023.07.901. Epub 2023 Jul 22.
2
Preoperative risk score (PreopScore) to predict overall survival after resection for hepatocellular carcinoma.用于预测肝细胞癌切除术后总生存期的术前风险评分(PreopScore)。
HPB (Oxford). 2023 Mar;25(3):353-362. doi: 10.1016/j.hpb.2022.12.009. Epub 2023 Jan 7.
3
A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Hepatocellular Carcinoma Patients Undergoing Curative-Intent Surgery.一种用于预测接受根治性手术的肝细胞癌患者术前微血管侵犯风险的新型在线计算器。
Ann Surg Oncol. 2023 Feb;30(2):725-733. doi: 10.1245/s10434-022-12494-0. Epub 2022 Sep 14.
4
A comprehensive preoperative predictive score for post-hepatectomy liver failure after hepatocellular carcinoma resection based on patient comorbidities, tumor burden, and liver function: the CTF score.基于患者合并症、肿瘤负担和肝功能的肝癌切除术后肝衰竭的综合术前预测评分:CTF 评分。
J Gastrointest Surg. 2022 Dec;26(12):2486-2495. doi: 10.1007/s11605-022-05451-5. Epub 2022 Sep 13.
5
Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.总体肿瘤负担决定了米兰标准以外的多结节性肝细胞癌患者切除术后的结局。
Ann Surg. 2020 Oct;272(4):574-581. doi: 10.1097/SLA.0000000000004346.
6
Impact of Surgical Margin Width on Prognosis Following Resection of Hepatocellular Carcinoma Varies on the Basis of Preoperative Alpha-Feto Protein and Tumor Burden Score.术前甲胎蛋白和肿瘤负担评分基础上手术切缘宽度对肝癌切除术后预后的影响。
Ann Surg Oncol. 2023 Oct;30(11):6581-6589. doi: 10.1245/s10434-023-13825-5. Epub 2023 Jul 11.
7
PIVKA-II combined with tumor burden score to predict long-term outcomes of AFP-negative hepatocellular carcinoma patients after liver resection.异常凝血酶原(PIVKA-II)联合肿瘤负荷评分预测 AFP 阴性肝癌患者肝切除术后的长期预后。
Cancer Med. 2024 Jan;13(1):e6835. doi: 10.1002/cam4.6835. Epub 2023 Dec 21.
8
An Eastern Hepatobiliary Surgery Hospital Microvascular Invasion Scoring System in Predicting Prognosis of Patients with Hepatocellular Carcinoma and Microvascular Invasion After R0 Liver Resection: A Large-Scale, Multicenter Study.东方肝胆外科医院微血管侵犯评分系统预测 R0 肝切除术后肝细胞癌伴微血管侵犯患者的预后:一项大样本、多中心研究。
Oncologist. 2019 Dec;24(12):e1476-e1488. doi: 10.1634/theoncologist.2018-0868. Epub 2019 May 28.
9
Development and validation of the OSASH score to predict overall survival of hepatocellular carcinoma after surgical resection: a dual-institutional study.开发和验证 OSASH 评分以预测肝癌手术后的总生存:一项双机构研究。
Eur Radiol. 2023 Nov;33(11):7631-7645. doi: 10.1007/s00330-023-09725-7. Epub 2023 May 16.
10
Multi-institutional validation of novel models for predicting the prognosis of patients with huge hepatocellular carcinoma.多机构验证新型模型预测巨大肝细胞癌患者预后的价值。
Int J Cancer. 2021 Jul 1;149(1):127-138. doi: 10.1002/ijc.33516. Epub 2021 Feb 27.

引用本文的文献

1
The Influence of Tumor Burden Score and Lymph Node Metastasis on the Survival Benefit of Adjuvant Chemotherapy in Intrahepatic Cholangiocarcinoma.肿瘤负荷评分和淋巴结转移对肝内胆管癌辅助化疗生存获益的影响
Ann Surg Oncol. 2025 Jun;32(6):4341-4351. doi: 10.1245/s10434-025-17013-5. Epub 2025 Feb 17.